Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Uptick in Q1 Revenues

NEW YORK, May 11 (GenomeWeb News) - Genaissance Pharmaceuticals today reported a 74 percent increase in first-quarter revenues, while its losses remained flat and R&D spending increased slightly.


For the three months ended March 31, 2004, the company reported $3.7 million in revenue, up from $2.1 million in the prior-year period.


Genaissance's net loss for the first quarter was $4.8 million, or $.21 per share, compared to $4.7 million, also $.21 per share, for the three months ended March 31, 2003.


The company spent $5.0 million on R&D during the first quarter of 2004, up from $4.7 million in the same period of 2003.


As of March 31, 2004, Genaissance had cash, cash equivalents, and marketable securities totaling $11.4 million, compared to $16.8 million as of Dec. 31. 2003.


Based on its acquisition of Lark Technologies, which closed April 2, Genaissance provided guidance for the remainder of 2004, projecting revenues "in excess" of $25 million, with a net loss of between $14 and $15 million.


Kevin Rakin, president and CEO of Genaissance, said the company expects to launch its first molecular test, called Familion, for cardiac ion channel mutations, later this month.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.